



29 October 2015

Resonance Health Ltd (ASX:RHT) Appendix 4C – 1st Quarter Cash Flow Report

Resonance Health Limited today released its 1st quarter Cash Flow Report for the period ending 30 September 2015.

Cash at 30 September 2015 was \$2.787million. Receipts from customers for the September quarter was \$605,000 and an R&D Tax Incentive of \$116,000 was received.

The marketing spend in the September quarter was \$151,000. Marketing continues to be focused and targeted towards key opinion leaders, patient disease associations and pharmaceutical drug companies.

During the quarter the Company:

- Appointed a new distributor in Canada
- Held a celebration with St Mary's Hospital (London, UK) to mark their milestone of 1000 FerriScans
- Established FerriScan on a mobile MR scanner in the UK
- Promoted FerriScan at the Annual Conference of the Sickle Cell Disease Association of America
- Travelled to Vietnam to speak at the Thalassaemia International Federation Pan-Asian Conference on Haemoglobinopathies

Research and development spend was in line with our planned budget of \$123,000 focused on further studies involving HepaFat-Scan and the development of a non-invasive liver fibrosis measurement technology.

During the quarter:

- The Company further refined its expertise in bone marrow iron assessments and has been actively discussing an opportunity to provide these measurements in a small pharmaceutical sponsored study
- The AASLD abstract for the Company's prototype liver fibrosis measurement technology was accepted. The abstract will be presented at the annual Liver Meeting which begins 13th November 2015
- The first patient was recruited for the clinical study to assess whether HepaFat-Scan can improve post-surgical outcomes when applied prior to liver surgery for the treatment of colorectal metastases
- The Company's partnership with CSIRO continued as we work with them to apply some of their expertise as part of our ongoing development of a non-invasive liver fibrosis measurement

The Company was also pleased to see our Chief Scientific Officer, Prof Tim St Pierre, receive the award for the Western Region EY Entrepreneur of the Year (Technology category).

Investors can subscribe to our ASX market releases via our web site.

<http://www.resonancehealth.com/investors/asx-subscribe.html>

For further information please contact:

Resonance Health

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: adrianb@resonancehealth.com

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

30 September 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	605	605
1.2 Payments for		
(a) staff costs	(311)	(311)
(b) advertising and marketing	(151)	(151)
(c) research and development	(123)	(123)
(d) leased assets	-	-
(e) other working capital	(119)	(119)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	20	20
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	116	116
1.7 Other Receipts/Payments		
(a) consulting & professional services	(8)	(8)
(b) statutory & compliance	(47)	(47)
(c) grants	-	-
(d) Due diligence expense	-	-
Net operating cash flows	(18)	(18)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitment

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)		
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(9)	(9)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	(9)	(9)
1.14	Total operating and investing cash flows	(27)	(27)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	-
	Net financing cash flows	-	-
	Net increase (decrease) in cash held	(27)	(27)
1.21	Cash at beginning of quarter/year to date	2,797	2,797
1.22	Exchange rate adjustments to item 1.20	17	17
1.23	Cash at end of quarter	2,787	2,787

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	\$35k
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	\$35K – Directors fees	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	537	537
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details) - Term deposits	2,250	2,250
Total: cash at end of quarter (item 1.22)	2,787	2,787

Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Adrian Bowers
Company Secretary